Press releases

Avita Medical Ltd today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Read More...

Avita Medical has been chosen as the winner of the esteemed Australia-Taiwan Business Excellence Award for 2015, presented in recognition of the support offered to the victims of the Formosa Waterpark Dust Explosion incident, in partnership with ShawHan Biomedical Group. The award was presented by......

Avita announced today the closing of a AUD$10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD$0.093 per share. Read More...

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, has been awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to USD$53.9 million for late-stage clinical development and procurement......

Adam Kelliher, CEO of Avita hosted an investor presentation in Melbourne today to interested parties on the recent BARDA announcement.  Please see AVH ASX for further information....

· VP and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals · 25 Years Management Experience in Pharmaceutical and Biotech Development · Substantial Venture Capital Expertise in Life Science Funds NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom,6 February 2013- Regenerative medicine company Avita Medical......